

Is Novoeight® right for you?

It's time to change the conversation
about your hemophilia A treatment

Julian, 25 years old, lives with hemophilia A.

What is Novoeight®?

- Novoeight® (antihemophilic factor, recombinant) is an injectable medicine used to control and prevent bleeding in people with hemophilia A. Your healthcare provider may give you Novoeight® when you have surgery
- Novoeight® is not used to treat von Willebrand Disease

Important Safety Information

Who should not use Novoeight®?

- You should not use Novoeight® if you are allergic to factor VIII or any of the other ingredients of Novoeight® or if you are allergic to hamster proteins

Please see additional Important Safety Information throughout.
Please see accompanying Prescribing Information.



novoeight®
Antihemophilic Factor
(Recombinant)

When it comes to choosing your factor, you have a voice!

Finding the right hemophilia A treatment to fit your lifestyle is important. Use this brochure to determine which features of a treatment matter most to you. Share those results with your health care provider and get the conversation started about why Novoeight® may be the right fit for you.



I want a factor that I can take with me everywhere, without refrigeration, even at high temperatures up to 104°F.

Strongly disagree Disagree Neutral Agree Strongly agree

How I store and travel with my factor when I'm on the go is important to me.

Strongly disagree Disagree Neutral Agree Strongly agree



The safety of my factor, including low risk of inhibitors, is crucial.

Strongly disagree Disagree Neutral Agree Strongly agree



Having a factor that controls bleeds in 1-2 infusions makes me feel like I can count on my treatment.

Strongly disagree Disagree Neutral Agree Strongly agree



I want to feel valued and supported by the company that makes my factor.

Strongly disagree Disagree Neutral Agree Strongly agree


Other important things about my treatment: _____

Notes/questions for my health care provider: _____

How Novoeight® fits your lifestyle. Portability. Safety. Effectiveness.

Higher degree of portability

- Highest storage temperature for the longest duration^a
 - up to **104°F** for up to 3 months
 - up to **86°F** for up to 12 months
- Highest storage temperature after reconstitution^a
 - up to 2-hour storage time up to **104°F**
- Longest room temperature storage time after reconstitution^a
 - up to 4-hour storage time up to **86°F**



Safety profile

- Over **9 years of clinical experience** with Novoeight® in previously treated patients
- One of the largest clinical trials of a recombinant FVIII to date showed **0 inhibitors** occurred in previously treated patients
- Common side effects of Novoeight® include inhibitors in patients who were not previously treated with factor VIII products

Effective bleed control

- Bleeds treated with 1 or 2 infusions
 - Nearly **9 out of 10 (89%)** of adults and adolescents aged 12-65
 - More than **9 out of 10 (95%)** of children aged 0-11
- **100%** of bleeds controlled for patients who had major and minor surgeries

^aCompared with other recombinant FVIII products. Please see Prescribing Information for complete product storage conditions.

Novo Nordisk, the maker of Novoeight®, is committed to helping the bleeding disorders community, with over 30 years of research, clinical experience, and support for people with bleeding disorders and their health care providers.

Important Safety Information

What is the most important information I need to know about Novoeight®?

- **Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia center**
- **Call your healthcare provider right away and stop treatment if you get any of the following signs of an allergic reaction:** rashes or hives, difficulty breathing or swallowing, tightness of the chest, swelling of the lips and tongue, light-headedness, dizziness or loss of consciousness, pale and cold skin, fast heartbeat, or red or swollen face or hands

Please see additional Important Safety Information on the back. Please see accompanying Prescribing Information.

novoeight®
Antihemophilic Factor
(Recombinant)

We're here to support you

Trial program

Visit MYNOVOSECURE.COM or call **1-844-NOVOSEC (1-844-668-6732)** to speak with a NovoSecure™ Specialist to find out if you're eligible to receive a limited supply of Novoeight® for free^a

^aPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance or who are uninsured, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.



Share your survey results with your health care provider and get the conversation started about Novoeight® today!



Be sure to visit Novoeight.com for more information.

Important Safety Information

What should I tell my healthcare provider before using Novoeight®?

- Before taking Novoeight®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
- Your body can make antibodies called “inhibitors” against Novoeight®, which may stop Novoeight® from working properly. **Call your healthcare provider right away if your bleeding does not stop after taking Novoeight®**

What are the possible side effects of Novoeight®?

- Common side effects of Novoeight® include inhibitors in patients who were not previously treated with factor VIII products, swelling or itching at the location of injection, and fever

Please see additional Important Safety Information throughout.

Please see accompanying Prescribing Information.



Novo Nordisk Inc., 800 Scudders Mill Road,
Plainsboro, NJ 08536 U.S.A.

Novoeight® is a registered trademark and NovoSecure™ is a trademark of Novo Nordisk Health Care AG. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2019 Novo Nordisk Printed in the U.S.A. US18NEG00132 January 2019

novoeight®
Antihemophilic Factor
(Recombinant)